Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Stealth BioTherapeutics

Nasdaq:MITO
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MITO
Nasdaq
$47M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The last earnings update was 135 days ago. More info.


Add to Portfolio Compare Print
  • Stealth BioTherapeutics has significant price volatility in the past 3 months.
MITO Share Price and Events
7 Day Returns
12.8%
NasdaqGM:MITO
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-89.9%
NasdaqGM:MITO
0%
US Biotechs
-11.5%
US Market
MITO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stealth BioTherapeutics (MITO) 12.8% -29.5% -62.6% -89.9% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • MITO underperformed the Biotechs industry which returned 0% over the past year.
  • MITO underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Stealth BioTherapeutics's competitors could be found in our database.

MITO Value

 Is Stealth BioTherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stealth BioTherapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stealth BioTherapeutics.

NasdaqGM:MITO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:MITO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.2 (1 + (1- 21%) (35.88%))
1.362
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.362 * 5.44%)
9.15%

Discounted Cash Flow Calculation for NasdaqGM:MITO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stealth BioTherapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:MITO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.15%)
2020 -111.39 Analyst x2 -102.05
2021 -124.00 Analyst x1 -104.08
2022 -9.00 Analyst x1 -6.92
2023 42.00 Analyst x1 29.59
2024 144.00 Analyst x1 92.95
2025 246.24 Est @ 71% 145.63
2026 369.92 Est @ 50.22% 200.43
2027 501.90 Est @ 35.68% 249.15
2028 629.87 Est @ 25.5% 286.46
2029 745.58 Est @ 18.37% 310.66
Present value of next 10 years cash flows $1,101.00
NasdaqGM:MITO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $745.58 × (1 + 1.74%) ÷ (9.15% – 1.74%)
$10,238.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,238.04 ÷ (1 + 9.15%)10
$4,265.91
NasdaqGM:MITO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,101.00 + $4,265.91
$5,366.91
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,366.91 / 36.39
$147.47
NasdaqGM:MITO Discount to Share Price
Calculation Result
Value per share (USD) From above. $147.47
Current discount Discount to share price of $1.29
= -1 x ($1.29 - $147.47) / $147.47
99.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Stealth BioTherapeutics is available for.
Intrinsic value
>50%
Share price is $1.29 vs Future cash flow value of $147.47
Current Discount Checks
For Stealth BioTherapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Stealth BioTherapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Stealth BioTherapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stealth BioTherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stealth BioTherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MITO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-4.31
NasdaqGM:MITO Share Price ** NasdaqGM (2020-03-27) in USD $1.29
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stealth BioTherapeutics.

NasdaqGM:MITO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MITO Share Price ÷ EPS (both in USD)

= 1.29 ÷ -4.31

-0.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stealth BioTherapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Stealth BioTherapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Stealth BioTherapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:MITO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
48.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Stealth BioTherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Stealth BioTherapeutics's assets?
Raw Data
NasdaqGM:MITO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.11
NasdaqGM:MITO Share Price * NasdaqGM (2020-03-27) in USD $1.29
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:MITO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MITO Share Price ÷ Book Value per Share (both in USD)

= 1.29 ÷ 0.11

12.23x

* Primary Listing of Stealth BioTherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stealth BioTherapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Stealth BioTherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Stealth BioTherapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MITO Future Performance

 How is Stealth BioTherapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stealth BioTherapeutics expected to grow at an attractive rate?
  • Stealth BioTherapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Stealth BioTherapeutics's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Stealth BioTherapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MITO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MITO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 48.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MITO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MITO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 261 147 76 4
2023-12-31 158 45 32 4
2022-12-31 102 -6 -17 4
2021-12-31 31 -104 -76 4
2020-12-31 2 -111 -86 4
2020-03-28
2019-12-31 8 -107 -88 6
NasdaqGM:MITO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -102
2019-06-30 -108
2019-03-31 -120
2018-12-31 -72 -97
2018-09-30 -69 -92
2017-12-31 -70 -83
2016-12-31 -54 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stealth BioTherapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Stealth BioTherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MITO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Stealth BioTherapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MITO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.12 0.16 0.06 3.00
2023-12-31 0.04 0.09 0.00 4.00
2022-12-31 -0.03 0.01 -0.07 4.00
2021-12-31 -0.15 -0.06 -0.24 4.00
2020-12-31 -0.18 -0.11 -0.29 6.00
2020-03-28
2019-12-31 -0.26 -0.17 -0.32 6.00
NasdaqGM:MITO Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -4.31
2019-06-30 -6.67
2019-03-31 -13.49
2018-12-31 -16.95
2018-09-30 -16.16
2017-12-31 -14.53
2016-12-31 -10.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Stealth BioTherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Stealth BioTherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stealth BioTherapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MITO Past Performance

  How has Stealth BioTherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stealth BioTherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stealth BioTherapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Stealth BioTherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Stealth BioTherapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Stealth BioTherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stealth BioTherapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MITO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -102.05 26.17 44.82
2019-06-30 -108.24 24.65 51.22
2019-03-31 -119.55 22.88 53.95
2018-12-31 -96.71 22.22 53.06
2018-09-30 -92.19 16.10 58.77
2017-12-31 -82.91 16.50 63.22
2016-12-31 -61.05 13.40 48.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Stealth BioTherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Stealth BioTherapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Stealth BioTherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Stealth BioTherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stealth BioTherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MITO Health

 How is Stealth BioTherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stealth BioTherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stealth BioTherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stealth BioTherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Stealth BioTherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stealth BioTherapeutics Company Filings, last reported 5 months ago.

NasdaqGM:MITO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 3.70 16.84 37.23
2019-06-30 19.29 16.76 53.20
2019-03-31 33.92 16.69 70.50
2018-12-31 -175.33 122.04 10.86
2018-09-30 -149.08 97.50 4.08
2017-12-31 -79.91 64.05 4.12
2016-12-31 1.55 0.00 9.71
  • Stealth BioTherapeutics's level of debt (455.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if Stealth BioTherapeutics's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Stealth BioTherapeutics's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Stealth BioTherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stealth BioTherapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MITO Dividends

 What is Stealth BioTherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stealth BioTherapeutics dividends.
If you bought $2,000 of Stealth BioTherapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stealth BioTherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stealth BioTherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MITO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MITO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stealth BioTherapeutics has not reported any payouts.
  • Unable to verify if Stealth BioTherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stealth BioTherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stealth BioTherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Stealth BioTherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stealth BioTherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stealth BioTherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MITO Management

 What is the CEO of Stealth BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Reenie McCarthy
AGE 54
TENURE AS CEO 1.4 years
CEO Bio

Ms. Irene P. McCarthy, also known as Reenie, J.D., has been President, Chief Executive Officer and Secretory of Stealth BioTherapeutics Incorporated since October 2018 and has been its Director since June 2018. Ms. McCarthy served as Investor Director of CellCentric Ltd. since October 16, 2015. Ms. McCarthy served as a Member of Morningside Technology Advisory, LLC (and affiliates), a private advisory company, from January 2009 to April 2016. Ms. McCarthy remains a Director of Morningside Technology Advisory, LLC. She has served as Chief Executive Officer of Stealth Delaware since February 2016 and as President and Secretary of Stealth Delaware since August 2015 and has been its Director since July 2009. She has served as a Director for numerous private biotechnology companies developing drugs across a broad spectrum of therapeutic focus areas. Ms. McCarthy was a Director of Biovex Group, Inc., a biotechnology company developing an oncolytic vaccine for melanoma and Head and neck cancer, from 2009 to 2011, when it was acquired by Amgen Inc. Prior to joining the Morningside group, Ms. McCarthy spent five years as a corporate lawyer with Richards & O’Neil LLP. Ms. McCarthy serves as a Director at Atreaon, Inc., Clean Membranes, Inc. and Delaware Power Systems Corp. Ms. McCarthy served as Director of DNAtriX, Inc. until November 2, 2017. Ms. McCarthy represents Morningside on several private company boards. She serves at Morningside Ventures. She served as a Director of CellCentric Ltd. since January 2011. Ms. McCarthy received her A.B., cum laude, from Bates College and her J.D. from the University of Pennsylvania Law School.

CEO Compensation
  • Insufficient data for Reenie to compare compensation growth.
  • Insufficient data for Reenie to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Stealth BioTherapeutics management team in years:

2.3
Average Tenure
57
Average Age
  • The tenure for the Stealth BioTherapeutics management team is about average.
Management Team

Reenie McCarthy

TITLE
President
AGE
54
TENURE
1.4 yrs

Rob Weiskopf

TITLE
Chief Financial Officer
AGE
68
TENURE
0.5 yrs

Henry Hess

TITLE
Chief Legal Counsel

Ben Bronstein

TITLE
Chief Medical Officer
AGE
69

Brian Blakey

TITLE
Chief Business Officer
AGE
57

Doug Weaver

TITLE
Chief Medical Officer
TENURE
3.2 yrs

Jim Carr

TITLE
Chief Clinical Development Officer
AGE
56
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Stealth BioTherapeutics board of directors in years:

1.8
Average Tenure
68
Average Age
  • The average tenure for the Stealth BioTherapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Gerald Chan

TITLE
Chairman of the Board
AGE
68
TENURE
1.8 yrs

Reenie McCarthy

TITLE
President
AGE
54
TENURE
1.8 yrs

Francis Chen

TITLE
Non-Employee Director
AGE
69
TENURE
1.8 yrs

Kevin McLaughlin

TITLE
Non-Employee Director
AGE
63
TENURE
1.8 yrs

Ed Owens

TITLE
Non-Employee Director
AGE
72
TENURE
2.6 yrs

Lu Huang

TITLE
Non-Employee Director
AGE
45
TENURE
1.8 yrs

Lou Lange

TITLE
Independent Director
AGE
70
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. Jan 20 Sell Nan Fung International Holdings Limited Company 02. Jan 20 07. Jan 20 -333,333 $3.16 $-1,018,094
31. Dec 19 Sell Nan Fung International Holdings Limited Company 27. Feb 19 26. Dec 19 -500,000 $4.54 $-2,078,767
X
Management checks
We assess Stealth BioTherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stealth BioTherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MITO News

Simply Wall St News

MITO Company Info

Description

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company’s product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.

Details
Name: Stealth BioTherapeutics Corp
MITO
Exchange: NasdaqGM
Founded: 2006
$46,947,486
36,393,400
Website: http://www.stealthbt.com
Address: Stealth BioTherapeutics Corp
190 Elgin Avenue,
George Town,
Grand Cayman, KY1-9005,
Cayman Islands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MITO SPONSORED ADS Nasdaq Global Market US USD 15. Feb 2019
Number of employees
Current staff
Staff numbers
57
Stealth BioTherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:13
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.